AzTrials
AzTrials

Intensive Care Unit (ICU)MEDICOSLEEPNCT07606495

Impact on Prognosis of Increased Sleep Quality Obtained by Personalized Night-time Nursing Care in Critically Ill Patients

A study testing Sleepscan device and Sleep-guided nursing care in people with Intensive Care Unit (ICU) and Sleep Disruption, run by Poitiers University Hospital at 7 sites in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Sleep disturbances are common among intensive care unit (ICU) patients and have been associated with difficult weaning from invasive mechanical ventilation, with an increased risk of endotracheal intubation. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Sleepscan device and Sleep-guided nursing care
Could I receive a placebo?
No, everyone receives an active treatment
How many people
460 participants
Where
7 sitesFrance
Study dates
16 Sep 2026to Jun 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients aged 18 years or older admitted to an intensive care unit
  • Conscious patients with a Richmond Agitation-Sedation Scale (RASS) score between -2 and +1
  • Patients without continuous sedation, regardless of ventilatory support
  • No indication for urgent intubation (<12 hours)
  • Informed consent from the relatives or the patient himself

Who cannot join

  • Brain tumor or neuropsychiatric disorders affecting sleep
  • Amission for stroke or epilepsy
  • Administration of sleep-modifying medication within 24 hours prior to randomization
  • Patients with skin lesions around the central right and left areas preclunding the placement of the electrodes
  • Patients with expected ICU length of stay less than 48 hours
  • Patients with limitation or withdrawal of life-sustaining therapies
Show all 9Show fewer
  • Patients already included in the study during a previous hospitalization
  • Patients under law protection (guardianship, conservatorship, or judicial protective measures)
  • People under protection (minors, persons deprived of liberty by a judicial or administrative decision, patients in emergency situations)

Trial locations and contacts

7 sites in 1 country. Contact the study team or a site near you to ask about taking part.

7 sites in 1 country

France7 sites, 7 recruiting
  • Vendée Hospital

    La Roche-sur-Yon

    Not yet recruiting
  • La Rochelle Hospital

    La Rochelle

    Not yet recruiting
  • Le Mans Hospital

    Le Mans

    Not yet recruiting
  • Poitiers University Hospital

    Poitiers

    Recruiting
  • Rennes University Hospital

    Rennes

    Not yet recruiting
  • Saintes Hospital

    Saintes

    Not yet recruiting
  • Tours University Hospital

    Tours

    Not yet recruiting

Other trials in France

About this study

Official title: Impact Sur le Pronostic en réanimation d'Une Augmentation du Sommeil Par Soins Nocturnes personnalisés : Essai Clinique randomisé Multicentrique

Sleep disturbances are common among intensive care unit (ICU) patients and have been associated with difficult weaning from invasive mechanical ventilation, with an increased risk of endotracheal intubation. Other studies have reported associations between sleep disturbances and prolonged ICU length of stay or the occurrence of delirium. Among the factors contributing to sleep impairment, nighttime care interventions have been identified as a major cause. The management of sleep disorders in the ICU remains complex and often disappointing, and no pharmacological treatment is currently formally recommended. Very recently, a considerable improvement of sleep quantity (+50%) and quality (doubling of deep sleep quantity) has been reported by reorganizing nighttime nursing care according to patients' sleep cycles, using a sleep monitoring medical device.

The objective of this study is to quantify the impact of a better sleep on prognosis. Sleep will be improved using sleep-guided nursing care during nighttime thanks to a real-time sleep monitor (Sleepscan°).

Read more

The primary endpoint is the proportion of patients requiring invasive mechanical ventilation or who have died at day 7 after inclusion. The main secondary outcomes include the duration of ICU stay, the number of delirium free-days, the score at a discomfort scale, the score at a post-traumatic stress disorder scale at ICU discharge. Intensive care unit-related costs will be assessed.

A multi-sites, prospective, randomized, open-label, superiority trial with two parallel arms will be conducted.

Awake and conscious patients without continuous sedation, regardless of ventilatory support, with no indication for urgent intubation (<12 hours) and with an expected ICU length of stay greater than 48 hours will be included.

The intervention will consist of sleep-guided nighttime nursing care using the Sleepscan monitor from 7:00 p.m. to 7:00 a.m., every night until ICU discharge or day 7. Sleep-guided nursing care consist in postponing non urgent care (such as temperature measurement…) and avoiding entering the room when patients are asleep. Otherwise, when patients are awake, instructions are to go for all care, to cluster and anticipate nursing care and perform comfort care.

In the control group, sleep will also be recorded using the same device but the tablet will not display the patient's sleep (or awake) status, and nighttime nursing care will be performed according to usual practice and independently of patients' sleep cycles.

Based on our preliminary data and previous studies, it has been estimated that 230 patients per group will be required to detect a reduction in the proportion of patients intubated or deceased at day 7 from 20% in the control group to 10% in the intervention group.

The intention-to-treat analysis population will include all randomized patients.

Demonstrating an improvement in patient prognosis through enhanced sleep quality would represent a major advancement for intensive care medicine. Reducing the need for invasive mechanical ventilation may lead to shorter ICU stays, lower mortality, fewer post-ICU complications, and reduced hospital costs. Demonstrating an improvement in patient prognosis through enhanced sleep quality would represent a major advancement for intensive care medicine. Reducing the need for invasive mechanical ventilation and the incidence of delirium may lead to shorter ICU stays, lower mortality, fewer post-ICU complications, and reduced hospital costs.

Being tested
Sleepscan device, Sleep-guided nursing care
Keywords
night-time nurse care, sleep promotion

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Sleepscan deviceDevice

    The Sleepscan® will be installed around 8:00 p.m., for both groups. For the control group, the tablet will not display the sleep/wake status. For the experimental group, the tablet will display the sleep/wake status.

  • Sleep-guided nursing careProcedure or surgery

    Nighttime nursing care will be guided by the Sleepscan device whether the patient is awake or asleep.

    When "Prioritize Sleep" signal will be displayed, caregivers may choose to postpone non-urgent care and reduce signal light and sound levels.

    When "Prioritize Care" signal will be displayed, caregivers prioritize care will be encouraged.

Study groups in NCT07606495
Study groupRoleWhat they receive
Control armActive comparatorStandard care with sleep recording using the Sleepscan® device.
Receives: Device: Sleepscan device
Experimental armExperimentalSleep-guided nursing carewith sleep monitoring using the Sleepscan® device.
Receives: Device: Sleepscan device; Procedure: Sleep-guided nursing care

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Patient prognosis

    Proportion of patients requiring invasive mechanical ventilation or who have died at day 7 after inclusion

    Measured: Day 7

Secondary outcomes (15)
  1. ICU length of stay

    Number of days in the ICU

    Measured: From date of randomization until the date of discharge from the ICU, assessed up to 90 days

  2. Hospital length of stay

    Number of days in the hospital

    Measured: Day 90

  3. Need for invasive ventilation

    Proportion of patients on invasive ventilation at 7 days.

    Measured: Day 7

  4. Death in the intensive care unit

    Proportion of patients who died in the intensive care unit

    Measured: From date of randomization until the date of discharge from the ICU, assessed up to 90 days

  5. Delirium free days

    Number of days without delirium, as defined by a negative score on the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) scale. The CAM-ICU is considered positive (confusion present) if criteria 1 and 2 + 3 or 4 are met.

    Measured: From date of randomization until the date of discharge from the ICU, assessed up to 7 days

  6. Delirium requiering treatment

    Proportion of patients treated for delirium during their stay in the intensive care unit.

    Measured: From date of randomization until the date of discharge from the ICU, assessed up to 7 days

  7. Patient discomfort

    Comfort score derived from the Scale of Perceived Discomfort in ICU Patients (IPREA) 18, assessed upon discharge from the ICU. The scale ranges from 0 (minimal discomfort) to 100 (maximum discomfort).

    Measured: Day of discharge from the ICU, assessed up to 90 days

  8. Post-traumatic stress symptoms

    Proportion of patients with post-traumatic stress disorder upon discharge from the intensive care unit, as assessed using the Revised Impact of Events Scale (IES-R) going from 0 (no post traumatic stress disorder) to 88 (severe post traumatic stress disorder).

    Measured: Day of discharge from the ICU, assessed up to 90 days

  9. Insomnia

    Average severity of sleep disturbances upon discharge from the intensive care unit, as measured by the Insomnia Severity Index (ISI) going from 0 (non insomnia) to 28 (severe insomnia).

    Measured: Day of discharge from the ICU, assessed up to 90 days

  10. ICU-related costs

    Average cost of a stay in the intensive care unit from admission to discharge, according to the national cost index

    Measured: From date of randomization until the date of discharge from the ICU, assessed up to 90 days

  11. Patient-reported sleep quality

    Average sleep quality perceived by the patient during their stay in the intensive care unit, as measured using the Richard-Campbell Sleep Quality Scale. It is based on five questions regarding falling asleep, sleep depth, the number of awakenings, time spent awake, sleep quality, and noise. A sixth question asks respondents to estimate the extent to which noise disturbs their sleep at night. Each item is scored on a scale of 0 (poor sleep quality) to 100 (high sleep quality).

    Measured: From date of randomization until the date of discharge from the ICU, assessed up to 7 days

  12. Nurses' workload

    Average workload for nurses related to sleep-guided nursing care, as measured using the National Aeronautics and Space Administration Task Load Index (NASA-TLX). Going from 0 (low workload) to 10 (high work load).

    Measured: From date of randomization until the date of discharge from the ICU, assessed up to 7 days

  13. Sleep duration

    Total sleep time in minutes, as measured by the Sleepscan® device.

    Measured: From date of randomization until the date of discharge from the ICU, assessed up to 7 days

  14. Mesured sleep quality

    Measured sleep quality will be assessed using three indicators from the Sleepscan® device:

    • The duration of sleep spent in episodes lasting > 10 minutes (in minutes and as a percentage).
    • The duration of deep sleep in stage N3 (in minutes and as a percentage of total sleep time)
    • The duration of REM sleep (in minutes and as a percentage of total sleep time).

    Measured: From date of randomization until the date of discharge from the ICU, assessed up to 7 days

  15. Artifacts of the system

    Proportion of nights with more than 50% artifacts

    Measured: From date of randomization until the date of discharge from the ICU, assessed up to 7 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 May 2026
  2. Study start16 Sep 2026
  3. Primary completionMar 2028 (estimated)
  4. Study completionJun 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
460 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07606495
Sponsor's protocol ID
2025-A02563-46
Acronym
MEDICOSLEEP
Status last verified
Sep 2026
First submitted
30 Apr 2026
Last updated
21 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Sleepscan device and Sleep-guided nursing care in people with Intensive Care Unit (ICU) and Sleep Disruption, run by Poitiers University Hospital at 7 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 21 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 7 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Xavier DROUOT (+33549444444, xavier.drouot@chu-poitiers.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Patient prognosis (time frame: Day 7). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2026; AzTrials last refreshed its copy on 7 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in